Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Hartkopf

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Breast Care (Basel, Switzerland)|June 19, 2024
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024Marc Thill, Wolfgang Janni, Ute-Susann Albert, et al.
Breast Care (Basel, Switzerland)|June 4, 2026
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026Marc Thill, Volkmar Müller, Tanja Fehm, et al.
Breast Care (Basel, Switzerland)|May 7, 2025
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025Marc Thill, Wolfgang Janni, Ute-Susann Albert, et al.
BMC Cancer|June 23, 2019
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM studyMarkus Wallwiener, Naiba Nabieva, Manuel Feisst, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 22, 2025
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025Toralf Reimer, Thorsten Kuehn, Volkmar Mueller, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
Journal of the National Cancer Institute|April 17, 2018
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysisFrançois-Clément Bidard, Stefan Michiels, Sabine Riethdorf, et al.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Research Square|November 19, 2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinomaDale Garsed, Tibor Zwimpfer, Sian Fereday, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Breast Care (Basel, Switzerland)|June 19, 2024
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024Marc Thill, Wolfgang Janni, Ute-Susann Albert, et al.
Breast Care (Basel, Switzerland)|June 4, 2026
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026Marc Thill, Volkmar Müller, Tanja Fehm, et al.
Breast Care (Basel, Switzerland)|May 7, 2025
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025Marc Thill, Wolfgang Janni, Ute-Susann Albert, et al.
BMC Cancer|June 23, 2019
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM studyMarkus Wallwiener, Naiba Nabieva, Manuel Feisst, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 22, 2025
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025Toralf Reimer, Thorsten Kuehn, Volkmar Mueller, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
Journal of the National Cancer Institute|April 17, 2018
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysisFrançois-Clément Bidard, Stefan Michiels, Sabine Riethdorf, et al.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Research Square|November 19, 2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinomaDale Garsed, Tibor Zwimpfer, Sian Fereday, et al.
Pageof 9